|
|
|
| Expression of MMP and VEGF in Primary Renal Cell Carcinoma and its Relationship with Clinical Features and Prognosis of Renal Cell Carcinoma |
| DAI Hong-liang, YANG Jing-zhe, CHEN Xiao-jun, et al |
| Dongfang Hospital of Beijing University of Traditional Chinese Medicine, 100078, Beijing |
|
|
|
|
Abstract 【Objective】 To investigate the expression of MMP and VEGF in primary renal cell carcinoma and its relationship with clinical features and prognosis of renal cell carcinoma. 【Methods】 A total of 72 cases of renal cell carcinoma confirmed by pathology in our hospital from January 2009 to June 2014 were selected, immunohistochemical staining was used to observe the expression of MMP-2, MMP-9 and VEGF in renal cell carcinoma, and the relationship between MMP-2, MMP-9 and VEGF expression and renal cell carcinoma was studied by unconditional Logistic regression. 【Results】 The expression of MMP-2,MMP-9,VEGF in renal cell carcinoma (RCC) increased gradually with the increase of TNM stage, and the difference was statistically significant among the different stages (P<0.05). In this group, 50 cases survived (the survival group), 22 cases died (the death group), the proportion of TNM stage Ⅰ-Ⅱ patients in the survival group was higher than that in death group (P<0.05). The expression of MMP2, MMP-9,VEGF in the dead group was significantly higher than that in the survival group (P<0.05). In TNM stage, MMP-2, MMP-9,VEGF was the main risk factor for the prognosis of renal cell carcinoma (OR=1.326, 1.559, 1.734, 1.846,P<0.05 ).【Conclusion】 The expression of MMP-2, MMP-9, VEGF in renal cell carcinoma is correlated with TNM stage and increases with the increase of TNM stage. MMP-2,MMP-9,VEGF are risk factors for the prognosis of renal cell carcinoma.
|
|
Received: 20 June 2018
|
|
|
|
|
|
[1] Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer[J].Nat Rev Clin Oncol,2014, 11(1):24-37.
[2] 向敏, 朱玲, 刘馨,等. 抗肿瘤血管生成靶向治疗进展[J].现代肿瘤医学, 2014,22(9):2237-2240.
[3] Wah TM, Irving HC, Gregory W,et al.Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours[J].BJU Int,2014, 113(3):416-428.
[4] 李英杰, 李贵明. 缺氧对肾癌ACHN细胞缺氧诱导因子1α及上皮钙黏素表达的影响[J].山西医药杂志, 2014,43(18):2142-2144.
[5] 王志向. 趋化因子受体CXCR4与肾癌转移研究进展[J].国际泌尿系统杂志, 2016, 36(3):443-447.
[6] 郑红芳, 丁厚中, 李巧星,等. 肾癌组织中HMGB1、MMP9的表达与临床分期、预后的相关性研究[J].中国现代医学杂志, 2016, 26(22):28-33.
[7] 杨亮, 乔振奎, 邴建勇,等. 基质金属蛋白酶和组织金属蛋白酶抑制剂在肾细胞癌组织中的表达[J].现代生物医学进展, 2014, 14(13):2446-2449.
[8] 赵仕佳, 叶向东, 肖磊,等. MMP-9与 VEGF在肾细胞癌中的表达及其临床诊断价值[J].实用癌症杂志, 2014,30(8):903-904.
[9] 乔振奎, 付培德, 王科亮,等. VEGF和Survivin在肾癌中的表达及其相关性研究[J].现代生物医学进展, 2014, 14(14):2657-2660.
[10] 卜宏民. MMP-2、MMP-9和VEGF在肾癌中的表达与临床意义[J].中国老年学, 2009, 29(13):1595-1597. |
|
|
|
2018, Vol. 35 
